ClinicalTrials.gg
CompletedNCT02477449Updated Aug 13, 2025

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

A Phase 1 interventional study of istaroxime and 9% Saline (NS) in Healthy, sponsored by Lee's Pharmaceutical Limited. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Lee's Pharmaceutical Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2015, registered Jun 2015).
Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Phase 1 study to investigate safety of istaroxime in healthy chinese volunteers.

Read the detailed description

32 subjects (F: M=1:1) were randomized in three dose groups (0.25-0.5-1.0ug/kg/min). 8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; 12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic. At least 1 week should be kept between two dose groups. Escalation to the higher dose will occur after the lower dose group has been completed and no significant safety issues are found.

02

Conditions studied

  • Healthy

Keywords

  • safety
  • istaroxime
03

In context

Lead sponsor

Lee's Pharmaceutical Limited is the lead sponsor of 74 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at 18-45 years (inclusive)
  2. Male or Non-pregnant, non-lactating women
  3. Chinese healthy subjects
  4. (BMI) at 19-24 kg/m2 (inclusive) and body weight at 50-100kg
  5. Lab examinations (include but not limited: , white blood cell counting, differential count, creatinine,Alkaline phosphatase (ALP), (AST), alanine aminotransferase (ALT),Total and urinalysis) are within normal range or out of normal range but no clinical significance.
  6. Vital signs in screening phase: SBP100-139mmHg, DBP 50-89 mmHg, pulse rate 45-90 bpm. Holter is within normal range or out of normal range but no clinical significance.
  7. Both physical examination and at baseline are normal or abnormal but no clinical significance
  8. Women of childbearing age during the trial must be willing to use a medically acceptable method of , which include surgical sterilization (tubal ligation / hysterectomy), and double barrier methods of hormonal contraception.
  9. Subjects well communicate with investigators, understanding the requirements of investigators and being willing to sign the ICF before conducting any study-related procedure.
  10. Subjects are willing to stay at the phase I ward throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Disease history in liver, kidney, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal tract, lungs, immune, skin, blood, or metabolic disorders or cancer, that may have great impact on the study results.
  2. Presence of pancreatitis, intestinal obstruction, glaucoma, prostatic hypertrophy, adrenal disease, hyperthyroidism or gallbladder disease (subjects had experienced cholecystectomy will not be excluded)
  3. History of clinical significant disease in the past 4 weeks before screening visit
  4. Presence of diseases which are known to disturb the absorption, distribution, metabolism or excretion of Istaroxime
  5. Physical examinations, medical history, , vital signs or lab examination are deemed to be abnormal and clinical significant
  6. Be intolerant or allergy to Istaroxime, lactose or any similar substances
  7. Significantly abnormal diets are conducted within 4 weeks before screening visit
  8. Blood donation or loss equal to or exceeds 400ml in the past 6 months
  9. Participating in the any other drug study in the past 3 months
  10. Administrated OTC drugs including vitamin supplements and herbal (Occasional use of paracetamol will not be excluded)
  11. Regular use of any prescription drug (Hormonal pills or hormone replacement therapy will not be excluded)
  12. Drinking beverage or eat food containing caffeinated / xanthine or poppy seed since 48 hours before study drugs administration; or drinking beverage or eat food containing grapefruit, oranges or Chinese tea 14 days before the study drug administration
  13. Receiving the therapy of drugs including cytochrome P450 3A4 or cytochrome P450 2C8 inhibitors or inducers (eg barbiturates, carbamazepine, erythromycin, phenytoin, thiazoline TZDs, Rifampin)
  14. Women at Lactation period or with positive pregnancy test
  15. Tongue piercing or lip piercing occurred 30 days before the study drug administration
  16. Smoke or tobacco is used 60 days before the study drug administration
  17. History of abusing any substance including infusion drugs, alcohol and opium
  18. Positive alcohol breathing test within 1day or drink alcohol within 1week
  19. Abusing drugs (include Opioids, oxycodone, methamphetamine, amphetamine, cannabinoids, cocaine, barbiturates, benzodiazepines class, methadone, buprenorphine and phencyclidine)
  20. History of heart disease
  21. Planning to be pregnant in the recent 3 months
  22. Participating any other interventional strudy in the past 30 days
  23. History of bronchial asthma or blood porphyria disease
  24. HbsAg, anti-, anti- or anti - syphilis are positive
  25. Holter examination is abnormal and clinical significant
  26. Subjects are not eligible for the study judged by investigators
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    low dose group

    8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.

    Drug: istaroxime

  • Experimental
    mid dose group

    12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.

    Drug: istaroxime · Drug: 9% Saline (NS)

  • Experimental
    high dose group

    12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.

    Drug: istaroxime · Drug: 9% Saline (NS)

Interventions

  • 8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).

  • Drug9% Saline (NS)

    infusion for 24 hours

06

What researchers measure

Primary outcomes

  1. safety of istaroxime in healthy volunteers is measured by varition of heart functon, blood pressure and heart ratio

    safety of istaroxime in healthy volunteers is measured by

    Time frame: one week

07

Study locations

1 site
  • The 307th hospital of chinese People's liberation army
    Beijing, 100071, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02477449
Collaborators
CVie Therapeutics Co. Ltd.
Responsible party
Sponsor
First posted
Jun 22, 2015
Start date
Mar 2015
Primary completion
Oct 2015
Completion
Oct 2015
Last update
Aug 13, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Istaroxime

Start the discussion